| Literature DB >> 35285425 |
Marwa Mohamed Atef1, Noha M Shafik1, Yasser Mostafa Hafez2, Mona Mohamed Watany3, Amal Selim2, Heba M Shafik4, Omnia Safwat El-Deeb1.
Abstract
BACKGROUND: Diabetic retinopathy (DR) signifies a frequent serious diabetic complication influencing retinal structure and function. Dysregulation of lncRNAs drives a wide array of human diseases especially diabetes; thus, we aimed to study lncRNA HIF1A-AS2 role and its interplay with hypoxia, oxidative stress (OS), and angiogenesis in DR.Entities:
Keywords: Diabetic retinopathy; HIF-1α; HIF1A-AS2; MAPK; VEGF; angiogenesis; endoglin; oxidative stress
Mesh:
Substances:
Year: 2022 PMID: 35285425 PMCID: PMC8928809 DOI: 10.1080/13510002.2022.2050086
Source DB: PubMed Journal: Redox Rep ISSN: 1351-0002 Impact factor: 4.412
Demographic and clinical data of the studied groups.
| Variable | Control | Diabetic without retinopathy | Nonproliferative diabetic retinopathy | Proliferative diabetic retinopathy | |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 8(53.33%) | 7 (46.67%) | 8(53.33%) | 9(60.00%) | |
| Female | 7 (46.67%) | 8(53.33%) | 7 (46.67%) | 6(40.00%) | |
| Age (years) | 50.47 | 52.53 | 50.67 | 54.02 | |
| Duration (years) | – | 2.60 | 7.47 | 13.60 | |
| BMI (kg/m2) | 28.35 | 33.82 | 35.12 | 34.45 | |
| FBG (mg/dl) | 91.33 | 171.47 | 205.80 | 225.20 | |
| Pp. BG (mg/dl) | 115.27 | 228.53 | 275.33 | 290.60 | |
| HbA1c (%) | 4.98 | 7.5 | 8.95 | 9.75 | |
| TC (mg/dl) | 189.47 | 216.73 | 256.87 | 264.47 | |
| TG (mg/dl) | 133.17 | 187.33 | 233.27 | 273.40 | |
| HDL-c (mg/dl) | 46.67 | 42.60 | 41.73 | 39.33 | |
| LDL-c (mg/dl) | 116.17 | 136.66 | 168.49 | 170.48 | |
| UACR (mg/g) | 23.47 | 201.27 | 286.47 | 361.0 |
Abbreviation: BMI: body mass index; FBG: fasting blood glucose; Pp. BG: 2h-post prandial blood glucose; HbA1c: glycated hemoglobin; TC: total cholesterol; TG: triacylglycerol; HDL-c: high-density lipoprotein–cholesterol; LDL-c: low-density lipoprotein–cholesterol; UACR: urinary albumin-to-creatinine ratio.
Statistical study is achieved using one-way ANOVA with Tukey’s post hoc test, SPSS computer program.
* Significant difference vs. control group (P < 0.05).
# Significant difference vs. diabetic group without retinopathy (P < 0.05).
▴Significant difference vs. nonproliferative diabetic retinopathy group (P < 0.05).
◊ Significant difference vs. proliferative diabetic retinopathy group (P < 0.05).
Biochemical parameters of the studied groups.
| Variable | Control | Diabetic without retinopathy | Nonproliferative diabetic retinopathy | Proliferative diabetic retinopathy | |
|---|---|---|---|---|---|
| HIF-1α level (pg/ml) | 87.60 ± 9.53 | 226.40 ± 42.25*▴◊ | 393.99 ± 57.42*# ◊ | 712.65 ± 84.74*#▴ | |
| VEGF level (pg/ml) | 98.51 ± 17.55 | 154.36 ± 22.40*▴◊ | 223.58 ± 24.33 *# | 244.16 ± 40.87*# | |
| Endoglin level (ng/ml) | 0.58 ± 0.17 | 2.12 ± 0.43*▴◊ | 3.34 ± 0.45 *# ◊ | 4.69 ± 0.75 *#▴ | |
| MAPK level (pg/ml) | 42.54 ± 6.62 | 69.18 ± 8.64*▴◊ | 85.58 ± 10.19*# ◊ | 99.40 ± 20.79*#▴ | |
| AGEs (U/ml) | 34.60 ± 6.98 | 74.20 ± 9.99*▴◊ | 93.60 ± 10.53*# ◊ | 119.10 ± 12.81*#▴ | |
| MDA level (nmol/L) | 61.87 ± 9.46 | 97.51 ± 10.49*▴◊ | 126.05 ± 11.56*# ◊ | 173.44 ± 24.43*#▴ | |
| TAC level (mmol/L) | 1.65 ± 0.15 | 1.03 ± 0.21*▴◊ | 0.91 ± 0.23*# ◊ | 0.87 ± 0.36*#▴ | |
| Total thiols level (μmol/ml) | 271.41± 12.60 | 219.57 ± 14.70*▴◊ | 192.28 ± 13.35*# ◊ | 173.39 ± 29.88*#▴ | |
| NO level (µmol/L) | 31.77 ± 5.97 | 44.15± 4.28*▴◊ | 51.52 ± 5.35*# ◊ | 59.11 ± 9.84*#▴ | |
| ONOO− level (µmol/L) | 3.91 ± 0.41 | 6.63 ± 0.55*▴◊ | 8.24 ± 0.61*# | 8.92 ± 1.67 *# |
Abbreviation: AGEs: advanced glycation end products; HIF-1α: hypoxia inducible factor 1-alpha; MAPK: mitogen activated protein kinase; MDA: malondialdehyde; NO: nitric oxide; ONOO−: peroxynitrite; TAC: total antioxidant capacity; VEGF: vascular endothelial growth factor.
Statistical study is achieved using one-way ANOVA with Tukey’s post hoc test, SPSS computer program.
* Significant difference vs. control group (P < 0.05).
# Significant difference vs. diabetic group without retinopathy (P < 0.05).
▴Significant difference vs. nonproliferative diabetic retinopathy group (P < 0.05).
◊ Significant difference vs. proliferative diabetic retinopathy group (P < 0.05).
Comet assay parameters obtained by image analysis in peripheral blood mononuclear cells of the studied groups.
| Variable | Control | Diabetic without retinopathy | Nonproliferative diabetic retinopathy | Proliferative diabetic retinopathy | |
|---|---|---|---|---|---|
| Tails length (µm) | 1.36 ± 0.06 | 2.35 ± 0.13*▴◊ | 4.58 ± 0.42*# ◊ | 9.75 ± 0.37*#▴ | |
| Tail DNA% | 1.46 ± 0.04 | 2.69 ± 0.06*▴◊ | 3.67± 0.08*# ◊ | 8.66 ± 1.01*#▴ | |
| Tail moment | 1.99± 0.08 | 6.32 ± 0.21*▴◊ | 16.81 ± 1.45*# ◊ | 84.60 ± 6.75*#▴ |
Note: Statistical study is achieved using one-way ANOVA with Tukey’s post hoc test, SPSS computer program.
* Significant difference vs. control group (P < 0.05).
# Significant difference vs. diabetic group without retinopathy (P < 0.05).
▴Significant difference vs. nonproliferative diabetic retinopathy group (P < 0.05).
◊ Significant difference vs. proliferative diabetic retinopathy group (P < 0.05).
Figure 1.Photomicrographs representation of DNA damage in peripheral blood mononuclear cells using comet assay in control group (A), diabetic group without retinopathy (B), nonproliferative diabetic retinopathy group (C), proliferative diabetic retinopathy group (D). (The scale bar is 40 µm, 5 fields were assessed to provide this representative image).
Figure 2.HIF1A–AS2 relative expression in the studied groups. Data are represented as mean ± SD. * Significant difference vs. control group (P < 0.05). # Significant difference vs. diabetic group without retinopathy (P < 0.05). ▴Significant difference vs. nonproliferative diabetic retinopathy group (P < 0.05). ◊ Significant difference vs. proliferative diabetic retinopathy group (P < 0.05).
Correlations between the studied parameters in diabetic retinopathy patients.
| Variable | HIF1A–AS2 | HIF-1α | VEGF | MAPK | Endoglin | MAPK | AGEs | |
|---|---|---|---|---|---|---|---|---|
| HIF1A–AS2 | ||||||||
| HIF-1α | 0.719 | |||||||
| <0.001* | ||||||||
| VEGF | 0.487 | 0.613 | ||||||
| <0.001* | <0.001* | |||||||
| MAPK | 0.460 | 0.644 | 0.813 | |||||
| <0.001* | <0.001* | <0.001* | ||||||
| Endoglin | 0.713 | 0.901 | 0.669 | 0.665 | ||||
| <0.001* | <0.001* | <0.001* | <0.001* | |||||
| AGEs | 0.888 | 0.902 | 0.821 | 0.835 | 0.893 | |||
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||||
| MDA | 0.578 | 0.800 | 0.834 | 0.829 | 0.785 | 0.829 | 0.871 | |
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||
| TAC | 0.264- | 0.335- | 0.626- | 0.641- | 0.477- | 0.641- | 0.783- | |
| <0.05* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||
| Total thiols | 0.448- | 0.619- | 0.827- | 0.885- | 0.675- | 0.885- | 0.863- | |
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||
| NO | 0.459 | 0.672 | 0.770 | 0.828 | 0.710 | 0.828 | 0.841 | |
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||
| ONOO− | 0.416 | 0.607 | 0.825 | 0.804 | 0.628 | 0.804 | 0.840 | |
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||
| Tail DNA% | 0.740 | 0.936 | 0.568 | 0.674 | 0.837 | 0.674 | 0.848 | |
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||
| Tail moment | 0.746 | 0.931 | 0.839- | 0.648 | 0.815 | 0.648 | 0.779 | |
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | ||
| HbA1c % | 0.470 | 0.673 | 0.395 | 0.401 | 0.624 | 0.401 | 0.859 | |
| <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* |
Abbreviation: AGEs: advanced glycation end products; HbA1c: glycated hemoglobin; HIF-1α: hypoxia inducible factor 1-alpha; HIF1A–AS2: HIF1A antisense RNA 2; MAPK, Mitogen activated protein kinase; MDA, Malondialdehyde; NO, nitric oxide; ONOO−, Peroxynitrite; TAC, Total antioxidant capacity; VEGF, Vascular endothelial growth factor. P < 0.05 is significant. r, Pearson’s correlation coefficient.
Multiple linear regression analysis for potential predictors of proliferative diabetic retinopathy.
| Unstandardized coefficients | Standardized coefficients | ||||
|---|---|---|---|---|---|
| Variable | B | Standard error | Beta | t | |
| HIF1A–AS2 | 0.460 | 0.161 | 0.407 | 2.863 | <0.001* |
| HIF-1α | 0.001- | 0.002 | 0.139- | 0.614- | 0.542 |
| VEGF | 0.002- | 0.003 | 0.074- | 0.530- | 0.599 |
| MAPK | 0.025- | 0.015 | 0.309- | 1.927- | 0.090 |
| Endoglin | 0.404 | 0.207 | 0.338 | 1.992 | <0.05 * |
| AGEs | 0.020 | 0.010 | 0.343 | 1.997 | <0.05 * |
| MDA | 0.014- | 0.009 | 0.319- | 1.562- | 0.125 |
| TAC | 0.587- | 0.754 | 0.110- | 0.779- | 0.440 |
| Total thiols | 0.014- | 0.010 | 0.281- | 1.323- | 0.792 |
| NO | 0.020 | 0.015 | 0.161 | 1.336 | 0.188 |
| ONOO− | 0.255 | 0.140 | 0.263 | 1.816 | 0.076 |
| Dependent variable: HbA1c % | |||||
Abbreviation: AGEs: advanced glycation end products; HbA1c: glycated hemoglobin; HIF-1α: hypoxia inducible factor 1-alpha; HIF1A–AS2: HIF1A antisense RNA 2; MAPK: mitogen activated protein kinase; MDA: malondialdehyde; NO: nitric oxide; ONOO−: peroxynitrite; TAC: total antioxidant capacity; VEGF: vascular endothelial growth factor. P < 0.05 is significant. r: Pearson’s correlation coefficient.